🇺🇸 FDA
Pipeline program

Ketamine

TAK-063_102

Phase 1 small_molecule completed

Quick answer

Ketamine for Ketamine-Induced Brain Activity Changes is a Phase 1 program (small_molecule) at TAKEDA PHARMACEUTICAL CO LTD with 1 ClinicalTrials.gov record(s).

Program details

Company
TAKEDA PHARMACEUTICAL CO LTD
Indication
Ketamine-Induced Brain Activity Changes
Phase
Phase 1
Modality
small_molecule
Status
completed

Clinical trials